Skip to content
The Nexus
DossierENTITY

GLP-1 business

Coverage of GLP-1 business in the Nexus archive.

Earliest in view: May 26 · 11:29 UTCMost recent: May 26 · 11:29 UTC
Co-mentioned in this coverage
Eli Lillyorganization1Curevoorganization1LimmaTech Biologicsorganization1Vaccine Companyorganization1cancertopic1autoimmune diseasestopic1sleep disorderstopic1
Recent coverage
  • BUSINESSMay 26 · 11:29 UTCSTAT NEWS
    STAT+: Eli Lilly to buy three small vaccine developers

    Eli Lilly announced it will acquire three early- and mid-stage vaccine developers—Curevo, LimmaTech Biologics, and Vaccine Company—for up to nearly $4 billion. The acquisitions follow recent purchases in cancer, autoimmune diseases, and sleep disorders, leveraging Lilly's cash reserves from its successful GLP-1 business.